Clinical characteristics and laboratory indicator analysis of 67 COVID-19 pneumonia patients in Suzhou, China
- PDF / 1,696,650 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 74 Downloads / 173 Views
RESEARCH ARTICLE
Open Access
Clinical characteristics and laboratory indicator analysis of 67 COVID-19 pneumonia patients in Suzhou, China Yi Wang1,2†, Lin Yao1,2†, Jian-Ping Zhang1,2†, Pei-Jun Tang1,2, Zhi-Jian Ye1,2, Xing-Hua Shen1,2, Jun-Chi Xu1,2* , Mei-Ying Wu1,2* and Xin Yu1,2*
Abstract Background: Sudden exacerbations and respiratory failure are major causes of death in patients with severe coronavirus disease 2019(COVID-19) pneumonia, but indicators for the prediction and treatment of severe patients are still lacking. Methods: A retrospective analysis of 67 collected cases was conducted and included approximately 67 patients with COVID19 pneumonia who were admitted to the Suzhou Fifth People’s Hospital from January 1, 2020 to February 8, 2020. The epidemiological, clinical and imaging characteristics as well as laboratory data of the 67 patients were analyzed. Results: The study found that fibrinogen (FIB) was increased in 45 (65.2%) patients, and when FIB reached a critical value of 4.805 g/L, the sensitivity and specificity、DA, helping to distinguish general and severe cases, were 100 and 14%、92.9%, respectively, which were significantly better than those for lymphocyte count and myoglobin. Chest CT images indicated that the cumulative number of lung lobes with lesions in severe patients was significantly higher than that in general patients (P < 0.05), and the cumulative number of lung lobes with lesions was negatively correlated with lymphocyte count and positively correlated with myoglobin and FIB. Our study also found that there was no obvious effect of hormone therapy in patients with severe COVID-19. Conclusions: Based on the retrospective analysis, FIB was found to be increased in severe patients and was better than lymphocyte count and myoglobin in distinguishing general and severe patients. The study also suggested that hormone treatment has no significant effect on COVID-19. Keywords: OVID-19, SARS-CoV-2, FIB, Treatment, Hormone
Background Novel coronavirus pneumonia is an acute infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is mainly transmitted by respiratory particles [1]. Since the first novel coronavirus pneumonia case was reported in Wuhan, China, the new coronavirus spread rapidly across the country, and it is also * Correspondence: [email protected]; [email protected]; [email protected] † Yi Wang, Lin Yao and Jian-Ping Zhang contributed equally to this work. 1 The Affiliated Infectious Hospital of Soochow University, 10, Guangqian Road, Suzhou, Jiangsu, P. R. China 215000 Full list of author information is available at the end of the article
endemic in many countries around the world, including Japan, Singapore, Thailand and the United States [2]. Thus far, thousands of cases have been confirmed. On February 11, 2020, the World Health Organization (WHO) officially announced that the cause of the new coronavirus pneumonia is a new variant of coronaviruses and named the disease that it caused as coronavirus disease 2019 (
Data Loading...
